New strategy of thrombolysis. Conjunctive effect of plasminogen activators with different pharmacokinetic profile

Combined actions of native and prolonged thrombolytics allow the use of lower doses and simplified schemes of administration, thus yielding significant results in experimental therapy regarding the efficacy and safety of thrombolysis. Development of prolonged forms of plasminogen activators and testing their effect in combination with the thrombolysis trigger are well founded and of current interest. Thrombolytic compositions on the basis of short- and long-term-acting plasminogen activators appear to be promising and potentially eligible for bolus administration.